Evaluation of small molecule ferroptosis inhibitors in a GPX4 ALS model

Active Project Grant Awarded Last action

Award ID
HT94252510162
Recipient
Awarding agency
Obligated
$879,721

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 80% complete
Place of performance
New York, NY 10027, USA

Award details come from USAspending.gov.

About this award

This $879,721 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research to evaluate small molecule ferroptosis inhibitors in a Gtp4-associated amyotrophic lateral sclerosis (ALS) model at Columbia University. The research aims to transform healthcare for military service members and the broader public by developing innovative medical solutions to address critical health challenges. The award is effective from April 1, 2025 through March 31, 2027. As a leading private research institution, Columbia University has an extensive track record of collaborating with federal agencies to advance national scientific and technological priorities through diverse research and development initiatives.

Subawards

Subrecipient Amount Awarded
University Of Texas Health Science Center Of San Antonio The University of Texas Health Science Center at San Antonio will support “Evaluation of small molecule ferroptosis inhibitors in a GPX4 ALS model.” Dr. Qitao… $95,622

Quick answers

Who received award HT94252510162?

HT94252510162 was awarded to The Trustees Of Columbia University In The City Of New York by Defense Health Agency (Department of Defense) on April 1, 2025.

How much is award HT94252510162 worth?

$879,721 has been obligated on HT94252510162.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award